Darshana Zaveri
Managing Partner @ Catalyst Health Ventures
Boston, United States
Darshana Zaveri is a Partner and a member of Catalyst’s investment committee. Darshana is actively involved in all aspects of Fund Management including Investments and Capital Raising. She led Catalyst’s investments in Augmenix, Lantos Technologies, nVision Medical, Maxwell Health, Aria CV and Hepregen. She is currently a Director of Lantos (pastChair), Aria CV and nVision and is an observer to the boards of Augmenix and Maxwell Health.Darshana brings to Catalyst over a decade of experience in the health care and Life Science Industries. Prior to Catalyst, she was an Investigator at Vertex Pharmaceuticals and an integral part of the drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company, at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles and currently serves as a Catalyst of the Deshpande Center for Technological Innovation at MIT.Darshana received an MPA from Harvard University, a Master in Cell and Molecular Biology from Boston University, and a BS in Biochemistry from Bombay University in Bombay, India.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 39%
Last updated:
For AI agents: llms.txt
Industries Darshana Zaveri invests in
Stages Darshana Zaveri invests in
Countries Darshana Zaveri invests in
Investment Focus
Industry
- Health Care 6 (26%)
- Medical Device 6 (26%)
- Biotechnology 3 (13%)
- Medical 2 (9%)
- Wellness 2 (9%)
Stage
- Series B 6 (26%)
- Series A 4 (17%)
- Series C 3 (13%)
- Venture - Series Unknown 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rejoni
|
Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $25M / Venture - Series Unknown / Jun 16, 2026 | |
Venova Medical
|
Venova Medical develops vascular access systems for patients requiring renal replacement therapy. It addresses patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for intervention. The company was founded in 2018 and is headquartered in Los Gatos, California. | $30M / Series B / Sep 04, 2024 | |
AtaCor Medical
|
AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. | $28M / Series C / Apr 24, 2024 | |
Instylla
|
Instylla’s focus is to leverage hydrogel technology . | $30M / Series C / Aug 15, 2023 | |
|
Rejoni
|
Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $26.3M / Series B / Dec 07, 2022 | |
Avive Solutions
|
Avive Solutions develops a next-generation Automated External Defibrillator (AED) and software solutions. Avive's AED enables anyone to positively impact the outcome of a Sudden Cardiac Arrest (SCA) rescue by building a more robust solution that addresses the problem of SCA in its entirety. The AED will remove barriers to respond to a SCAscenario. It will be easy to purchase, easy to access in an emergency, easy to keep maintained, and most importantly easy to use effectively when it matters most.Avive Solutions is headquartered in San Francisco, California. | $22M / Series A / Mar 16, 2022 | |
PanTher Therapeutics
|
PanTher Therapeutics is on a mission to revolutionize cancer care with a proprietary treatment platform designed to enhance therapeutic response with minimal side effects. PanTher’s highly adaptable platform empowers oncologists to treat patients with life-threatening cancer by unlocking a drug’s full potential through direct, sustained treatmentat the tumor site. This distinctive targeting capability uniquely positions PanTher to take on the deadliest and most difficult to treat cancers with a lead investigational candidate in pancreatic cancer. | $5.4M / Series A / May 19, 2021 | |
|
PanTher Therapeutics
|
PanTher Therapeutics is on a mission to revolutionize cancer care with a proprietary treatment platform designed to enhance therapeutic response with minimal side effects. PanTher’s highly adaptable platform empowers oncologists to treat patients with life-threatening cancer by unlocking a drug’s full potential through direct, sustained treatmentat the tumor site. This distinctive targeting capability uniquely positions PanTher to take on the deadliest and most difficult to treat cancers with a lead investigational candidate in pancreatic cancer. | $5.4M / Series A / May 19, 2021 | |
|
Instylla
|
Instylla’s focus is to leverage hydrogel technology . | $25.4M / Series B / Oct 14, 2020 | |
|
Instylla
|
Instylla’s focus is to leverage hydrogel technology . | $25.4M / Series B / Oct 14, 2020 | |
| See all 23 investments → | |||
Co-Investors
About Catalyst Health Ventures
Catalyst Health Ventures is an early-stage venture capital firm targeting technology solutions applied within the health care and life science industries. At the core of this strategy is a committed, hands-on approach to working with management and syndicate partners to build successful companies. Their disciplined investment process leverages bothintellectual and financial capital to originate deals, cultivate opportunities, and realize the full potential of emerging ventures in the health care and life science marketplace. We seek to invest in companies addressing major global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. We invest in pioneering and proprietary technological solutions fundamentally designed to reduce treatment costs and improve patient outcomes. By investing in solutions which have a technological foundation of engineering and development such as medical devices, diagnostic tools and instrumentation and consumer healthcare, we minimize the risks related to uncertain scientific experimentation.
Catalyst Health Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Darshana Zaveri
Managing Partner
|
|||
David Mackey
Chief Financial Officer
|
|||
Joshua Phillips
Managing Partner
|
|||
Joshua S. Phillips
Managing Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Darshana Zaveri invest in?
Darshana Zaveri invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series B and Series A stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Darshana Zaveri last invest?
The most recent investment recorded for Darshana Zaveri closed in Jun 2026. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
